Clinical observations on safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 2, 2010, Pages 553-555

  Yao, Cheng Yun ^a   Huang, Xin En ^a   Tang, Jin Hai ^a   Xu, Hong Xia ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

Chemotherapy; Fixed dose rate; Gemcitabine; Toxicity

Indexed keywords

EID: 78650705200     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Abbruzzese JL, Grunewald R, Weeks EA, et al (1991). A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol, 9, 491-8.
2. Attia S, Morgan-Meadows S, Holen KD, et al (2009). Doseescalation study of fixed- dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol, 64, 45-51.
3. Felici A, Di Segni S, Milella M, et al (2009). Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. Clin Pharmacokinet, 48,131-41.
4. Früh M, Gillessen S, Cerny T, et al (2008). Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non- small-cell lung cancer. Lung Cancer, 62, 344-50.
5. Gandhi V, Plunkett W. (1990). Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleoside. Cancer Res, 50, 3675-3680.
6. Grunewald R, Kantarjian H, Keating MJ, et al (1990). Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine(Gemcitabine) administration in leukemia. Cancer Res, 50, 6823-6.
7. Guan Z, Wang Y, Maoleekoonpairoj S, et al (2003). Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer, 89, 1865-9.
8. Heinemann V, Hertel LW, Grindey GB, et al (1988). Comparison of the cellular pharmacokinetics and toxicity of 2', 2'-difluorodeoxycytidine and 1-beta-D- arabinofuranosylcytosine. Cancer Res, 48, 4024-31.
9. Heinemann V, Xu Y-Z, Chubb S, et al(1990). Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxcytidine. Mol Pharmacol, 38,567-572.
10. Huang P, Chubb S, Hertel LW, et al (1991). Action of 2',2-difluorodeoxycytidine on DNA synthesis. Cancer Res, 51,6110-7.
11. Huang P, Plunkett W. (1995). Fludarabine and gemcitabineinduced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol, 36,181-8.
12. Kaba H, Fukuda H, Yamamoto S, et al (2004). Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0. Gan To Kagaku Ryoho, 31, 1187-92.
13. Martin C, Pollera CF.(1996). Gemcitabine: safety profile unaffected by starting dose. Int J Clin Pharmacol Res, 16, 9-18.
14. Massacesi C, Burattini L, Marcucci F, et al (2005). Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma. J Interferon Cytokine Res, 25, 165-8.
15. Noble S, Goa KL. (1997). Gemcitabine - A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs, 54, 447-72.
16. Poplin E, Feng Y, Berlin J, et al (2009). Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 27, 3778-85.
17. Shin SJ, Kim H, Baek JH, et al (2008). Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma. Lung cancer, 60, 83-91.
18. Tempero M, Plunkett W£̈ruiz Van Haperen V, et al (2003). Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion inpatients with pancreatic adenocarcinoma. J Clin Oncol, 21, 3402-8.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16.